Abstract The objective of the work reported in this paper was to critically assess how sequential disease-modifying anti-rheumatic drugs (DMARDs) have been modelled in the context of economic evaluation of the use of DMARDs for treatment of rheumatoid arthritis (RA). A secondary purpose was to identify the methodological challenges of modelling sequential therapies. Systematic searches of 10 databases were undertaken in February 2013. Studies were included if they were in the English language and a full comparative economic evaluation was reported. They were appraised by use of the Drummond checklist (Appendix to this paper). Data extracted included economic evaluation data, data relating to sequential treatment, and data on the modelling methods used. Fifty-seven studies were identified, with 25 (44 %) modelling a sequence of treatments. Fortythree (75 %) were cost-utility analyses. Eleven (19 %) were UK studies and 11 (19 %) were US. The remainder were mainly European (26 (46 %)). A distinction was made between studies of recent-onset RA (14 (25 %)) and those of established RA (42 (74 %)). One study (1 %) was unclear. Individual-level models were more likely to meet the Drummond criteria and evaluate sequences. No study identified an optimum sequence of multiple treatments given a set of treatment options. The level of reporting of the methods and evidence used to assess the effect of downstream treatments in the sequence was generally poor. When lifelong models and downstream treatment sequences were considered, evidence gaps were identified. The review discovered that methods have not been consistently applied, leading to varied estimates of cost-effectiveness. Treatment sequences have not been fully considered and modelled, potentially resulting in inaccurate estimates of cost-effectiveness.
Introduction
Rheumatoid arthritis (RA) is a chronic, progressive, autoimmune disease affecting approximately 0.8 % of the adult population [1] . RA affects the physical, psychological, and social health of patients and is associated with premature mortality [2] . Because the typical age of onset is 40 years, there is a substantial effect on direct health costs and on societal costs associated with lost productivity [3] . Current management of RA involves use of disease-modifying antirheumatic drugs (DMARDs) and glucocorticoids to retard disease progression. Analgesics and anti-inflammatories are used to treat symptoms. These treatments are used sequentially, because of the chronic nature of the condition and the limited efficacy of DMARDs over time. If disease control is not established, an alternative DMARD is used.
Conventional DMARDs (cDMARDs), including methotrexate, sulfasalazine, and leflunomide, are relatively inexpensive and, thus, a small proportion of the overall cost of treating RA [4] . Newer "biologic" DMARDs (bDMARDs) have had a substantial impact on patient care. The effectiveness of tumor necrosis factor-α (TNF-α) inhibitors-infliximab, adalimumab, and etanercept-has been established in randomised controlled trials (RCTs) [5] [6] [7] [8] [9] [10] [11] [12] and confirmed in meta-analyses [13] [14] [15] . More recently, bDMARDs with alternative mechanisms, for example rituximab, tocilizumab, and abatacept, and new TNF-α inhibitors-certolizumab pegol, and golimumab-have become available commercially. The optimum use of bDMARDs in the treatment sequence is subject to debate, in part because of their high cost. The UK National Health Service (NHS) currently allows bDMARDs only after ≥2 cDMARDs have been tried and have failed [16] .
Although RCTs are the recommended means of estimating a treatment's effectiveness, short-term RCTs are not sufficient for estimating long-term cost-effectiveness against a chronic disease such as RA. It is, therefore, necessary to combine evidence from several sources, including expert estimates, in a mathematical model to enable estimation of costs and benefits over a lifetime. These mathematical models (known as decision-analytic models) are a simplified representation of reality that describe the long-term experience of a patient and capture the costs and patient health-related quality of life over time. Modelling is now of crucial importance when undertaking economic evaluations and providing information on which to base health resource allocation decision making [17] .
In RA, different methods have been used to evaluate the costeffectiveness of DMARDs [18] . This has resulted in inconsistent evaluation of the same treatment among similar populations, and debate regarding the most appropriate methods and evidence to be used in decision-analytic models. A particular problem has been the sequencing of DMARDs, in which failure of one DMARD results in a change to another. This has caused a move from pair-wise comparison of small numbers of treatments to comparison of lifelong sequences of treatments.
The objective of this systematic review is to summarise economic evidence for the use of DMARDs in RA. The review will assess the strengths and limitations of specific economic evaluations and draw generalised conclusions regarding the methods currently used to evaluate treatment sequences for RA.
Review Methodology
Systematic searches of online databases were undertaken to identify all economic evaluations of DMARDs for RA published in English. To ensure high sensitivity, the search was developed by applying economic terms to a general disease search for RA and DMARDs. The disease component of the search was based on a strategy for the NICE rheumatoid arthritis guideline [19] . Database filters from the InterTASC Information Specialists' Sub-Group (ISSG) website (www.york.ac.uk/inst/ crd/intertasc/) were used to identify economic evaluations. The search strategy was reviewed by an information specialist.
Studies published any time up to February 2013 were identified by searching BIOSIS, Cochrane (Database of Systematic Reviews, Databases of Methodological Reviews, Central Register of Controlled Trials), DARE, CINAHL, Embase, MEDLINE, NHSEED, and SCI-WoS. Econlit was not searched because of the good coverage of the other databases. Studies were included if they met three criteria:
1. they were economic evaluations of intervention intended to alleviate the disease of people with RA; 2. they included a comparison of costs and benefits based on outcomes data or undertaken using decision-analytic methods; and 3. they reported costs and health outcomes.
Partial or non-comparative economic evaluations were excluded, as also were conference abstracts, methodological papers, studies without cost and effectiveness outcomes, and nonEnglish language papers. Studies were appraised by use of the Drummond "Critical appraisal of a published article" checklist (the completed checklist for all the studies is given in the Appendix to this paper) [20] . This checklist was chosen because it is a commonly used and validated economic evaluation appraisal tool. Data extracted included general economic evaluation data (analytical approach, population, sequences of intervention, length of study, treatment history, health economic results). Data concerning the treatment sequences modelled, and how this was undertaken, were also extracted. Data on any modelling methods used were also extracted. Systematic reviews of economic evaluations in RA were cross-checked to ensure all relevant articles were found.
Search Results
Fifty-seven evaluations were included in the review. A PRISMA diagram detailing the selection of studies is given in Fig. 1 . Forty-three (75 %) were cost utility analyses (CUAs) with quality adjusted life years (QALYs) as the metric of health outcome. Eleven (19 %) studies used a UK perspective, and 11 (19 %) a US perspective. The remaining studies were mainly from Europe (26 (46 %)). Fourteen (25 %) studies were of patients with recent-onset RA (no previous DMARD therapy). Forty-two (74 %) studies were of patients with established RA (previous DMARD therapy). One study (1 %) was unclear with regard to whether the treatment was for recent-onset or established RA. Table 1 provides a summary of the recent-onset studies (and the unclear study), and Table 2 provides a summary of the established RA studies.
Critical Appraisal of Studies of Recent-Onset RA In this section the 14 studies providing economic evidence for treatments of recent-onset RA [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] are critically appraised.
Scope of Economic Evaluations of Disease-Modifying Therapies for Recent-Onset RA
Details of all the recent-onset RA economic evaluations are summarised in Table 1 . All 14 studies were CUAs, with effects quantified as QALYs. Ten (71 %) of the studies considered the initiation of a specific therapy [21, 22, 24, 25, [27] [28] [29] [30] [31] 33] , and four (29 %) studies considered the tapering or adjustment of a treatment or combination of treatments [23, 26, 32, 34] .
The studies were diverse in their treatment considerations. Since 2006, seven studies (50 %) have evaluated the use of bDMARDs for recent-onset RA [21-23, 25, 27, 28, 34] . Before 2006, six studies(43 %) were published which evaluated the economic impact of cDMARDs [24, 26, [29] [30] [31] 33 ]. This leaves one study (7 %) evaluating cDMARDs at a point in the sequence where bDMARDs are used, with lifelong use [32] . After the launch of bDMARDs in the early 2000s, 2006 was approximately the time when evidence for these drugs had matured, so there was, understandably, a shift in the focus of economic evaluations from cDMARDs to bDMARDs to determine their cost-effectiveness. The NICE guidance for adalimumab, etanercept, and infliximab was published in 2007 [16] .
Six (43 %) of the studies were explicitly reported as being of an active RA population [21, 24, 29, [32] [33] [34] . Disease severity among the patient population being evaluated was not clearly reported by all the studies. Kobelt et al. (2011) evaluated etanercept plus methotrexate against methotrexate alone among a severe RA population [25] , and evaluated methotrexate plus sulfasalazine against leflunomide for any patient with RA [30] . In the remaining six (43 %) studies, patient population and disease severity was not reported [22, 23, [26] [27] [28] 31] .
Only in five (36 %) of the recent-onset RA studies was the economic evaluation performed for lifelong use [21-23, 28, 32] . Of these five studies, four were evaluations of bDMARDs for recent-onset RA, and all four used decisionanalytic modelling methods to estimate costs and effects [21] [22] [23] 28] . These included that by Chen et al. (2006) , a publication of the independent submission made by a NICE Technology Appraisal Group based at Birmingham, UK [21] . Only one study considered the lifetime costs and effects of alternative cDMARD monotherapy and combination therapy for treatment of recent-onset RA [32] .
Four studies (29 %) were for no longer than two years [24, 29, 31, 34] . Such short studies are likely to omit future costs and effects that occur between alternative treatments, in particular if a DMARD therapy is assumed to have a diseasemodifying effect on the future course of a chronic condition in RA.
Ten of the 14 (71 %) studies used decision-analytic modelling methods to determine expected costs and QALYs [21-23, 25, 26, 28, 30, 32, 33] . The other four studies (29 %) were economic evaluations in conjunction with clinical trials [24, 29, 31, 34] . Before 2006, six studies (43 %) evaluated the economic impact of cDMARDs, with none lasting longer than 10 years [24, 26, [29] [30] [31] 33 ]. Three of the six studies (50 %) undertook an economic evaluation in conjunction with a clinical trial [24, 29, 31] . Which partially explains the shortness of the study. Extrapolation or modelling of costs and effects may not be a primary objective when reporting a clinical trial; however the results of these studies will be of restricted use for resource allocation decision-making.
Downstream Costs and Effects for Recent-Onset RA
In the five lifelong economic evaluation studies, only Chen et al. (2006) explicitly modelled a downstream sequence of treatments [21] . The analysis enabled consideration of multiple positions of bDMARDs. However the authors did not attempt to identify an optimum treatment sequence from the set of treatments available.
Of the other four studies, considered alternative cDMARD monotherapy and combination therapy for recent-onset RA [32] . TNF-α inhibitors were not considered, because of the evaluation being used to provide information for the NICE Clinical Guideline, and the NICE guidance at that time recommending that TNF-α inhibitors be used only after treatment failure with at least two cDMARDs [19] . Lifelong studies would have enabled the implications of faster access to bDMARDs (by using combination rather than sequential monotherapy cDMARDs) to be quantified; however, the downstream bDMARDs were not explicitly modelled, and, instead, estimates of expected costs and QALYs from another study were added. Spalding et al. (2006) [27] . After bDMARD use the model contained a transition to a combination of cDMARDs, although the effect of this on costs and effects was not reported. Van den Hout et al. (2009) compared monotherapy and a combination of cDMARD therapies with initial infliximab plus methotrexate therapy, over a two year period [34] . The analysis was an economic evaluation alongside a clinical trial, and in the trial patients progressed to another active therapy after a failure. The trial was reported as intention to treat (ITT), so the costs and effects of transition to downstream sequential therapies were included in the economic evaluation.
The other four studies were short-term with no explicit inclusion of downstream costs and effects [24, [29] [30] [31] . All four studies are relatively old (1998) (1999) (2000) (2001) (2002) (2003) (2004) and are evaluations of cDMARDs. For these treatments, there was less of a focus on future benefits, for example disease control and joint damage, and more of a focus on short-term reduction of disease activity. Three of the four studies were clinical trials [24, 29, 31] , and [26] . It suffered from the same limitations, and also from the fact that it did not take into account disease duration or diminished clinical response for cDMARDs used later in the sequence.
The four Markov models defined health states and transition probabilities to move through different states. Two defined these health states on the basis of health assessment questionnaire (HAQ) scores, one by disease activity score (DAS), and one simply by either being on an active treatment or dead [26] , and with time dependent costs and utilities [31] .
The four individual sampling models explicitly modelled sequential treatments and all fully met the Drummond criteria The six older studies evaluating cDMARDs for recent-onset RA were less likely to meet the Drummond checklist for assessing the quality of the study [24, 26, [29] [30] [31] . Only fully met the Drummond criteria [26] . The other studies, in general, were not long enough to fully capture future costs and benefits [24, [29] [30] [31] 33 ], and did not report a fully incremental analysis of differences between alternatives [24, 29, 33] . Probabilistic sensitivity analysis was not usually performed: however, if detailed and comprehensive scenario and one-way analyses were performed, this was considered to be an appropriate level of testing for uncertainty.
Of the eight newer studies, five fully met the Drummond criteria [21-23, 32, 34] . Kobelt et al. (2011) [25] [28] did not clearly detail the evidence used to establish the programme's effectiveness, and the last two studies did not fully report incremental results.
Health Economic Results for Recent-Onset RA
Seven studies (50 %) evaluated the economic impact of cDMARDs for patients with recent-onset RA [21-23, 25, 27, 28, 34, 35] . Three of these studies evaluated combination cDMARD strategies, and all three found that a combination of cDMARDs outperformed monotherapy with cDMARDs [29, 31, 32] . Of the other four studies, three evaluated leflunomide monotherapy. estimated an incremental cost-effectiveness ratio (ICER) for leflunomide of $Can71k per QALY compared with a cDMARD sequence [26] . concluded that leflunomide can outperform or is outperformed by sulfasalazine and methotrexate, depending on the clinical evidence used to derive effectiveness [30] . Schadlich et al. (2005) estimated that adding leflunomide to a cDMARD sequence generated additional QALYs, with an ICER of €8 k per QALY. Hartman et al. (2004) estimated that folic acid as adjunct to methotrexate was outperformed by placebo, and folinic acid outperformed placebo [24] .
In the seven studies (50 %) evaluating the economic impact of bDMARDs for patients with recent-onset RA, the general conclusion was that bDMARDs added both incremental costs and incremental benefits compared with cDMARDs [21- [23] .
Of the 14 studies, six (43 %) reported that the results were robust when sensitivity analysis was conducted [27, [29] [30] [31] 33 , 35]. It was not possible to clearly identify the criteria used to suggest the results were robust. It was also not possible to check whether rigorous testing had been performed. Eight studies reported significant uncertainty [21-26, 28, 32, 34, 37] , with four studies (29 %) reporting specific model variables which led to significant sensitivity of the economic model. These were the rate of progression of HAQ scores while on treatment [21, 22] , the algorithm used to convert HAQ scores to utility [22] , the initial effectiveness [21] , the rate of withdrawal of cDMARDs [22] , and the initial change of HAQ score after a treatment response [28] .
Critical Appraisal of Studies in Established RA
This section is a critical appraisal of 42 studies providing economic evidence for treatment of established RA .
Scope of the Economic Evaluations of Disease-Modifying Therapies for Established RA
Details of all the established RA economic evaluations are summarised in Table 2 [48, 49] , one used per patient improved [38] , one used HAQ improvement [68] , and one used DAS improvement [72] . Two studies (5 %) were cost-consequence analyses (CCAs) [57, 63] , and two (5 %) were costminimisation analyses (CMAs) [67, 69] .
The studies were diverse in their treatment considerations; only four (9 %) were exclusively for cDMARDs [38, 63, 68, 72] . This probably reflects the development of bDMARD therapy in the last 15 years, and its relatively high price requiring formal economic evaluation to determine whether it offers value for money for use for patients with established RA.
In 14 (33 %) of the 42 studies, disease severity among the patient population being evaluated was not clearly reported [38, 41, 46 [42, 58, 68, 72, 80] , and one was an economic evaluation combined with a clinical trial [63] . None of these six studies was for longer than two years.
Downstream Costs and Effects in Established RA
In the 19 studies with lifelong economic evaluation, 13 (68 %) explicitly modelled a downstream sequence of treatments [39, 41, 45, 46, 51, 53-56, 62, 64, 74, 81] . None of these studies attempted to estimate the optimum sequence of treatments from the set available.
Bansback et al. (2005) evaluated bDMARDs with or without adjunct methotrexate versus cDMARDs for patients who had already failed two previous cDMARDs [39] . The cDMARD sequence was explicitly modelled, but the sequence was fixed for all comparisons. Hallinen [74] . In this case the sequence is likely to be too short and omitted other cDMARD options and sequential bDMARD use for this patient population. Diamantopoulos et al. (2012) compared alternative positions of tocilizumab for bDMARD naïve and experienced populations [53] . Kielhorn et al. (2008) evaluated the introduction of rituximab plus methotrexate after people had failed on two previous bDMARDs [56] . The downstream sequence, or position of rituximab plus methotrexate, was not altered. Lindgren et al. (2009) evaluated the introduction of rituximab after failure on one previous bDMARD [62] . The subsequent sequence of treatments was not altered. Merkesdal et al. (2010) evaluated the introduction of rituximab after failure on one previous bDMARD [66] . The subsequent sequence of cDMARDs was not altered, and no comparison with other bDMARDs was made.
Six studies (72 %) were lifelong but did not explicitly model the downstream treatments [40, 73, [75] [76] [77] 79] . Barbieri et al (2005) simulated HAQ states with associated costs and utilities [40] . Soini et al. (2012) modelled progression to best supportive care, but did not clearly report how costs and health-related quality of life were estimated [73] . Vera-Llonch et al. (2008) used the same model for two analyses, and after treatment withdrawal moved on to a linear extrapolation of HAQ with mapped estimates of costs and utilities [75, 76] . Wailoo et al. (2008) also extrapolated HAQ after treatment withdrawal [77] . Wong et al. (2002) estimated future costs and health effects by attributing a health state to each possible HAQ value. For the first-line treatment, an improvement in HAQ was possible; for downstream treatments, however, it was assumed no improvement in HAQ was possible. This method is likely to underestimate the effectiveness of subsequent therapy [79] .
Twenty-three of the 42 studies (55 %) of established RA were not lifelong studies. Of these, only six (26 %) explicitly modelled a downstream sequence of treatments [44, 50, 52, 70, 71, 78] . These studies were no longer than five years, and only Coyle et al. (2006) considered more than one downstream treatment in the sequence (the other five modelling only a switch to one other active therapy) [52] .
Seventeen studies were truncated, and with no explicit inclusion of long-term costs and effects [26, 38, 42, 43, 47-49, 57-61, 65, 67-69, 72] . The justification for this omission of long-term future costs and effects is not clear in any of the studies. Five studies are observational analyses [42, 58, 68, 72, 80] , and one is an evaluation combined with a trial [63] , so long-term modelling may not have been the primary research objective.
Decision-Analytic Modelling Methods for Established RA
As already mentioned, 36 (86 %) of the 42 studies used decision-analytic modelling methods to determine the expected costs and QALYs [38-41, 44-57, 59-62, 64-67, 69-71, 73-79] . Five (14 %) of the 36 models were a decision tree [38, [47] [48] [49] 70] , nine (25 %) were cohort Markov models [40, 52, 59-61, 65, 74, 78, 79] , and 16 (44 %) were individual patient models [39, 41, 45, 46, 51, 53-56, 62, 64, 66, 73, 75-77] . For the remaining six (17 %) studies, the method of decisionanalytic modelling was unclear [44, 50, 57, 67, 69, 71] .
Of the five decision tree models [38, [47] [48] [49] 70] , none was for longer than two years, and only Russell et al. (2009) considered sequential use of therapies [70] . Moving on to a second therapy was determined by achieving either LDAS or remission, and the evidence for this was not clearly reported.
The nine Markov models were also limited in considering the costs and effects of future treatment [40, 52, 59-61, 65, 74, 78, 79] . Only five met the Drummond criteria [59, 61, 65, 74, 79] , only three were lifelong [40, 74, 79] , and only three considered sequential treatments [52, 74, 78] .
The 16 individual level simulations were for lifelong treatment [39, 41, 45, 46, 51, 53-56, 62, 64, 66, 73, 75-77] . Twelve of these studies also considered sequential use of therapies for patients with established RA [39, 41, 45, 46, 51, 53, 54, 56, 62, 64, 66] . All 12 determined a treatment switch on the basis of either a short-term lack of response or long-term withdrawal because of loss of efficacy or an adverse event. In six models initial response was modelled by using an ACR response mapped to an HAQ improvement [39, 46, 53, 54, 56, 66] . Brennan et al. (2007) modelled initial treatment response by using the European League Against Rheumatism (EULAR) response categories and mapping the response to EQ-5D (or SF-6D) via a multivariate regression [45] .
Only 17 of the 42 (40 %) met the Drummond checklist for assessing the quality of the study [41, 45, 46 
Health Economic Results in Established RA
The main health economic results for each study are listed in Table 2 . None of the studies tried to identify the optimal sequence of treatments from the treatment set included in the analysis. Four of the 42 studies (10 %) were exclusively for cDMARDs among patients with established RA [38, 63, 68, 72] . observed in a one-year economic evaluation combined with a clinical trial that methotrexate outperformed leflunomide and placebo [63] . Osiri et al (2007) concluded that methotrexate plus antimalarials outperformed antimalarials, and non-methotrexate strategies were unlikely to be cost effective [68] . Shini et al. (2010) performed a CEA with change in HAQ as the measure of health benefit [72] . Their study suggested that hydroxychloroquine is the most cost effective monotherapy cDMARD strategy, with methotrexate plus hydroxychloroquine the most cost effective combination strategy. Anis et al. (1996) estimated an ICER of cyclosporine therapy of $1 k per patient improved compared with placebo [38] .
Nineteen studies (45 %) were non-sequential evaluations of bDMARDs among patients with established RA [40, 42, 43, 47-49, 57, 60, 61, 65, 67, 69, 73, 75-77, 79] . In general, the studies found that bDMARDs were more effective but also more costly than cDMARDs for patients with established disease. This conclusion was consistent across all studies, irrespective of country, patient population, or method of evaluation. Six of the 19 studies were lifelong decision-analytic models [40, 73, 75- Nineteen studies (45 %) were evaluations of alternative sequences of bDMARDs among patients with established RA [39, 41, 44-46, 50-56, 62, 64, 66, 70, 71, 74, 78] . Thirteen of these studies were lifelong, and, as before, these studies found sequential bDMARD use to be more effective but also more costly [39, 41, 45, 46, 51, 53-56, 62, 64, 66, 74] .
Four studies evaluated the introduction of rituximab into a sequence of DMARDs. [66] concluded that rituximab was cost-effective after TNF-α inhibitor failure compared with TNF-α inhibitors. Kielhorn et al. (2008) found that rituximab after two TNF-α inhibitor failures was costeffective [56] . None of the studies considered the optimum position of rituximab, comparing rituximab after one or two TNF-α inhibitor failures.
Of the nine remaining studies, nearly all were consistent in concluding that bDMARDs were likely to be cost effective. The only studies to conclude that, after two cDMARDs, bDMARDs were unlikely to be cost-effective compared with further cDMARD treatment were those of Barton et al. (2004) [41] and Jobanputra et al. (2002) [55] .
Six studies explicitly modelled a sequence of downstream treatments, but with short treatment time [44, 50, 52, 70, 71, 78] . These studies reported that bDMARDs were less likely to be cost effective. The short time of the treatment may therefore omit important downstream health benefits from bDMARDs, for example delayed joint erosion or disease progression.
Twenty-two of 42 (52 %) studies reported that the results were robust when sensitivity analysis was conducted [40, 41, 44, 48, 50, 52-54, 56-59, 61, 62, 64, 67, 69, 71, 75, 76, 78, 79] . As with the similar conclusion from the recent-onset RA population, it was unclear which criteria were used to suggest the results were robust or whether testing was sufficiently rigorous. Eight studies (19 %) reported significant uncertainty [39, 45-47, 49, 55, 65, 73] , with six studies (14 %) reporting specific model variables which led to significant sensitivity in the economic model. These were:
& the baseline age in the model [39] ; & the standardised mortality ratios [39] ; & the algorithm used to estimate health-related quality of life [39, 45, 65] ; & the rate of disease progression [45, 46] ; & discount rates [45] ; & treatment response rates [47] ;and & cost data [49] .
Discussion
Three key themes were identified in this systematic review of economic evaluations of sequential disease modifying therapies for rheumatoid arthritis.
First, the review highlights the significant number of uninformed decisions made in the care of patients with RA. Fourteen economic evaluations of therapy for a recent-onset RA population were identified, and 42 for an established RA population. Evaluations were undertaken for people with no previous treatment, to patients having had cDMARDs and two bDMARDs. There were several potential positions for each type of DMARD therapy, and the review identified approximately 30 discrete treatments. As a result of the huge number of potential comparators, therefore, no study attempted to determine the optimum sequence of therapies. The evaluation by Chen et al. (2006) was the only attempt from 57 evaluations to determine whether bDMARDs should be used to treat recent-onset or established RA [21] . However the evaluation included only a small subset of the available sequences. This review identified a substantial number of constrained or pair-wise evaluations, most of which did not conduct a fully incremental analysis or discuss the possibility of alternative positions other than the primary analysis. This is not particularly surprising, because each study was undertaken in its own particular decision-making context. The heterogeneity in terms of comparators, sequences, and methodology reflect both local and national variation and also the context in which health economic evaluation is conducted. A clear finding was that combinations of cDMARDs are important in the treatment of RA, and seem to be dominant or cost-effective at early positions in a sequence.
Second, modelling methodology was associated with the quality of the study and the ability to evaluate alternative sequences. Lifelong models were more likely to be individual patient simulations, and Markov and decision-tree models were less likely to evaluate sequential treatments. In all studies, the quality of reporting of the effect of future treatments on cost and health benefits was variable. However, in several sensitivity analyses the long-term progression of disease was shown to be a key variable for model sensitivity. Conversion from HAQ score to utility was also a source of uncertainty, and is a methodological challenge detailed in other published studies [82] [83] [84] .
Finally, when downstream treatments were explicitly modelled, the evidence used in support of this part of the model was from disparate sources, and was poorly reported.
Evidence used was often referred to rather than explicitly stated. In several evaluations assumptions of equal efficacy between treatments, or potential treatment decrements for later positioning within a sequence, was assumed when direct evidence was not identified, yet quantitative or qualitative evidence in support of these assumptions was not provided. The assumptions led to significant uncertainties in the evaluations, and also revealed that when cDMARDs or bDMARDs can be regarded as a class with similar costs and health effects, small assumptions can have a significant effect on a treatment's cost-effectiveness. Therefore it is important to identify and combine all relevant evidence to provide information for models, not just at the divergence point, but also throughout the complete model pathway. Because of these issues, it is not clear whether failure to address methodological issues regarding sequence modelling has led to inaccurate results of evaluations of specific treatments in a specific sequence.
Sullivan et al. recently systematically reviewed the economic evidence for sequencing bDMARDs in RA [85] . The review had a different perspective, and focussed solely on the cost-effectiveness evidence identified. As with this review, they found that the evidence was uncertain and unclear, and recommendations were hard to make. Our review builds upon this by focussing on methodological and evidence base issues which remain unresolved with the intention of improving future economic evaluations.
As with any systematic review, there are limitations that should be considered. The review does not include noneconomic evaluations, or purely disease modelling studies. Some studies which modelled sequences of treatments may have been omitted if no comparison between alternative strategies was presented. Second, some aspects of the data extraction were, to some extent, subjective. Where possible, checkbox choices and the Drummond checklist were used to ensure bias was minimised. However, when considering particular modelling methodologies subjective decisions by the reviewer were necessary. To minimise bias, the reviewer relied on what was reported by the author as fact. Identified systematic reviews of economic evaluations in RA were crosschecked when data extraction overlapped. Also, data regarding the "rebound" assumption made in the model when patients withdraw from treatment were not extracted. The rebound assumption is contentious and without supporting evidence, and sequential models rely on an assumption every time a treatment is changed [86, 87] . Further research on this issue is required. Finally, manufacturer's submissions to organisations such as NICE were not included, because full-text versions of their reports are not publicly available.
The review has highlighted issues when trying to undertake an economic evaluation of sequential therapy. These are both methodological challenges when developing models and decision-making issues when attempting to develop guidance based on evidence of cost-effectiveness. In particular, the factorial rate of growth in the number of comparator sequences is infeasible for standard decision-analytic models. Enumerating every possible sequence is not likely to be practical because the computational time and evidence requirements would be enormous. Use of heuristic methods from operational research to seek a near-optimum sequence, and methods to improve the tractability of developed models, may be potential solutions. Reviews and analysis will be undertaken to identify methodological solutions, with the purpose of developing a methodological framework for economic evaluation of sequential therapy for chronic conditions. Although the problem is significant in RA, there are other conditions in which this framework may be relevant, including multiple sclerosis, depression, psoriatic arthritis, and Crohn's disease. Any further research should be generalisable for these conditions also [88, 89] .
Conclusions
This review identified 57 unique economic evaluations of disease-modifying therapy for people with RA. Almost half modelled sequences of DMARDs. None of the studies identified considered identifying the most cost-effective sequence from all the treatment available. This has, therefore, led to clinical guidance being developed without the required economic evidence being available to ensure that health resource allocation decisions are fully informed, and therefore that the optimum allocation of resources has been identified. Twenty-four (42 %) life-long models have been developed, and 25 (44 %) had a downstream treatment sequence. In these studies, evidence gaps were identified. These include efficacy of treatments in downstream positions and the long term impact of treatments on costs and on health-related quality of life in the future. The review has identified that methods have not been consistently applied, which has led to varied estimates of cost-effectiveness and uncertainty in respect of the most appropriate analysis for addressing particular questions relevant to a decision. Research is required to develop a methodological framework for economic evaluation of sequential therapy for chronic conditions. 
